Artificial Intelligence & Generative AI
Speakers who decode the real-world impact of machine intelligence on industries, workforces and competitive advantage
Customers and employees rarely behave the way strategy decks predict. Brand teams optimise messages, pricing models test cleanly, CX programmes look complete on paper, and the actual revenue, retention and engagement numbers still drift. The gap is the human one, and most commercial functions have no disciplined way to close it.
Digital transformation programmes routinely stop at the edge of the human body. Leadership teams know identity, authentication, health data, and workforce capability are converging into something more intimate than a mobile device, but they have no shared language for what that means for products, security policy, or talent. The question is not whether human augmentation arrives in serious organisations, but how a board prepares for it without becoming either dismissive or naive.
Most leadership teams still make their biggest calls inside a small room of senior people who broadly agree with each other. The cost is slow decisions, narrow options, and innovation programmes that surface the same ideas the company already has. The harder question is how to widen the input set, employees, customers, partners, networks, without losing speed or accountability.
Boards are being asked to make consequential bets on generative AI without a stable read on what the technology can actually do, what it cannot, and what its deployment will mean for the workforce. Most executive briefings collapse into either hype or alarm. Leaders need a sober technical interpreter who can separate marketing from mechanism, and tell them which decisions matter now.
Most large organisations have funded AI programmes and run pilots. Most of those pilots never reach production. The gap is not technical capability. It is the absence of an outcome architecture that connects experimentation to structural change. Meanwhile, boards are approving AI investment without the governance frameworks to manage the risks that sit inside AI agents and automated decision-making systems.
Most organisations are not short of signals about technological change – they are short of a coherent way to read them. AI, robotics, quantum computing, and biotech are not arriving in sequence; they are arriving together, and their strategic implications compound. The real risk is not moving too slowly on one technology. It is misreading how several converging forces will combine to reshape a sector before the organisation has positioned itself to respond.
Most large organisations talk about innovation as culture and end up funding pilots that never reach the P&L. The gap is not ideas, it is process: how a bank, telco or pharma company moves a creative concept through the same operational rigour it applies to risk, finance and supply. Without a repeatable method, innovation stays personality-led and stops when the sponsor leaves.
Boards have signed off on AI ambitions that the operating business has no idea how to execute. Pilots multiply, vendor decks pile up, and the gap between strategy slides and what customers actually experience keeps widening. The job leaders need help with is choosing where AI changes the commercial model, and where it is noise.
Most change programmes stall in the gap between what leaders ask people to do and what people actually do. Restructures, AI rollouts and new operating models depend on behaviour change inside a workforce that is already tired of being changed. The leadership question is no longer what to do; it is how to get a real human organisation to follow through.
Boards understand cybersecurity as a compliance line item. They do not understand it as an active counterintelligence problem, where adversaries study the organisation, build trust with employees, and move on patient timelines. The same psychological playbook now drives AI-generated deepfakes, voice cloning and synthetic identity attacks against finance teams, executives and supply chains.
The integration of brain data, AI, and consumer-grade neurotechnology is moving faster than most senior leaders realise. The organisations engaging with this territory now will set the terms others have to accept later. Most boards do not yet have a real position on it.
Artificial intelligence is moving from pilot to protocol inside hospitals, space agencies, and infrastructure programmes, and most leadership teams are still arguing about what is real and what is theatre. The cost of getting this wrong is not slower innovation. It is patient harm, missed regulation, and capital deployed against the wrong assumptions. Boards want a translator who has actually built and deployed clinical AI, not a commentator describing it from the outside.